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Abstract
Background: Brachytherapy, interstitial tumor bed irradiation, following conservative surgery has
been shown to provide excellent local control and limb preservation in patients with soft tissue
sarcomas (STS), whereas little is known about the tolerance of peripheral nerves to brachytherapy.
In particular, nerve tolerance to high-dose-rate (HDR) brachytherapy has never been properly
evaluated. In this study, we examined the efficacy and radiation neurotoxicity of HDR
brachytherapy in patients with STS in contact with neurovascular structures.
Methods: Between 1995 and 2000, seven patients with STS involving the neurovascular bundle
were treated in our institute with limb-preserving surgery, followed by fractionated HDR
brachytherapy. Pathological examination demonstrated that 6 patients had high-grade lesions with
five cases of negative margins and one case with positive margins, and one patient had a low-grade
lesion with a negative margin. Afterloading catheters placed within the tumor bed directly upon the
preserved neurovascular structures were postoperatively loaded with Iridium-192 with a total
dose of 50 Gy in 6 patients. One patient received 30 Gy of HDR brachytherapy combined with 20
Gy of adjuvant external beam radiation.
Results: With a median follow-up of 4 years, the 5-year actuarial overall survival, disease-free
survival, and local control rates were 83.3, 68.6, and 83.3%, respectively. None of the 7 patients
developed HDR brachytherapy-induced peripheral neuropathy. Of 5 survivors, 3 evaluable patients
had values of motor nerve conduction velocity of the preserved peripheral nerve in the normal
range.
Conclusion:  In this study, there were no practical and electrophysiological findings of
neurotoxicity of HDR brachytherapy. Despite the small number of patients, our encouraging
results are valuable for limb-preserving surgery of unmanageable STS involving critical
neurovascular structures.
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Background
Success in the management of soft tissue sarcomas (STS)
is often limited by the extension of lesions to neurovascu-
lar structures, because of the difficulty in dissecting the
neurovascular bundle from the tumor without compro-
mising the function and local recurrence of residual
lesions. Patients with STS involving or extending to neu-
rovascular structures may be sometimes advised to
undergo an amputation. In an effort to preserve limbs,
conservative surgery with various modalities such as nerve
resection with or without nerve grafts, irradiation, and
hyperthermia for preservation of peripheral nerves has
been reported [1-4]. Brachytherapy, interstitial tumor bed
irradiation, following conservative surgery has been
shown to provide excellent local control and limb preser-
vation in patients with STS, whereas little is known about
the tolerance of peripheral nerves to brachytherapy. The
placement of afterloading catheters directly upon neurov-
ascular structures to irradiate such lesions appropriately
subjects them to high dose radiation. The American
Brachytherapy Society suggested that brachytherapy, espe-
cially high-dose-rate (HDR) brachytherapy, should be
used with caution in such situations [5].
We treated 7 patients with conservative surgical resection
and placement of afterloading catheters directly upon
these critical structures followed by fractionated HDR
brachytherapy. The purpose of this study was to evaluate
the efficacy and radiation neurotoxicity of HDR brachy-




Between 1995 and 2000, thirty patients with STS were
treated in our institute with limb salvage surgery followed
by fractionated HDR brachytherapy, after obtaining
informed consent from the patients or their guardians.
Among them, 7 patients with STS involving the neurovas-
cular bundle were enrolled in this study. The median age
at the time of the surgery was 53 years (range, 15–84).
There were 4 males and 3 females. All of the 7 patients
presented with primary tumors without distant metasta-
sis. Three patients had malignant fibrous histiocytoma,
two patients had myxoid liposarcoma, one patient had
synovial sarcoma, and one had extraskeletal chondrosar-
coma. The median tumor size, defined as the maximum
diameter of the tumor at pathological analysis, was 9.4 cm
(range, 5.5–13.0 cm). Three patients received periopera-
tive systemic therapy, which mainly consisted of ifosfa-
mide and doxorubicin. The clinical and pathological
characteristics of the patients are listed in Table 1.
Table 1: Patients' clinicopathological characteristics
No Sex Age (years) Histology Site Preserved nerve Tumor grade Size (cm)
1 Female 78 Myxoid liposarcoma Forearm Median, Radian, Ulnar High 13.0
2 Male 48 Malignant fibrous histiocytoma Thigh Sciatic High 5.5
3 Female 48 Myxoid liposarcoma Forearm Median High 5.5
4 Male 35 Malignant fibrous histiocytoma Thigh Sciatic High 9.0
5 Male 61 Extraskeletal chondrosarcoma Pople Popliteal Low 10.0
6 Female 15 Synovial sarcoma Buttock Sciatic High 10.0
7 Male 84 Malignant fibrous histiocytoma Buttock Sciatic High 13.0
Table 2: Treatment results
No. Margin PTVa (cm3) Brachytherapy (Gy) EBRTb (Gy) Failure Complication Follow-up 
(months)
1 Negative 65 50 - - Motor paresis AWDc (77)
2 Negative 63 50 (50) Local Fracture AWD (75)
3 Negative 52 50 - - - AWD (62)
4 Negative 93 50 - - - AWD (43)
5 Negative 64 30 20 - Sensory loss AWD (34)
6 Negative 60 50 - Lung - DODd (32)
7 Positive 134 50 - - - DOCe (13)
PTVa = Planning target volume, EBRTb = External beam radiation therapy, AWDc = Alive without disease, DODd = Dead of disease, DOCe = Dead 
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Surgery and HDR brachytherapy
All of the STS involving or adjacent to neurovascular struc-
tures were able to be marginally resected with careful dis-
section of these critical structures. The pathological
examination of surgical specimens demonstrated that
there were no gross residual lesions and one microscopic
positive margin, which was defined as tumor cells present
at the resection margins. A microscopically negative mar-
gin was defined as no tumor cells at the margins. In all 6
lesions with negative margins, tumor cells were seen
within 1 mm from the margins at the neurovascular bun-
dle (Table 2).
The brachytherapy technique has been previously
described [5,6]. In brief, the technique of brachytherapy
used afterloading catheters placed intraoperatively in the
tumor bed as a single plane implant. The afterloading
catheters with a 1 cm spacing in between were placed
within the surgical bed directly upon the preserved neu-
rovascular bundles. The catheters were located either par-
allel or vertical to the limb axes. The afterloading catheters
were fixed in position in the target region using absorba-
ble sutures and secured to the skin at the catheter exit site
with buttons. Postoperative localization films, along with
opaque dummy sources inserted into each individual
catheter, were taken to confirm the position of the cathe-
ters and for contouring and HDR brachytherapy planning.
The three-dimensional treatment planning was per-
formed by the Nucletron PLATO planning station (Nucle-
tron Corp., Columbia, MD) according to the International
Commission on Radiation Units and Measurements
(ICRU) Repost 58 [7]. The clinical target volume (CTV)
was defined by expanding the resected tumor bed by 0.5
cm margins. The planning target volume (PTV) was
defined by expanding the CTV by 1.0 cm margins on the
catheter plane. The PTV ranged from 52 to 134 cm3
(mean, 76). Multiple dose prescription points (5 mm
from the source axis) were defined in accordance with the
each dwell position. The prescribed dose at the periphery
of the PTV was 5 Gy per fraction. The PTV was expected to
cover the whole dissected portion of the nerve because the
width of the nerve was less than 5 mm in all patients.
Seven to ten days after the implantation, the catheters
were loaded with nominal 10 Curie Iridium-192 using
Microselectron-HDR (Nucletron Corp., Columbia, MD).
The total dose was 50 Gy, administered as 5 Gy per frac-
tion. Treatments were given twice a day over 5 days with a
minimum of 6 hours between fractions. However, Patient
5 with low-grade extraskeletal chondrosarcoma received
30 Gy of HDR brachytherapy as a boost combined with 20
Gy of adjuvant external beam radiotherapy (EBRT) (Table
2).
Electrophysiological study
Motor nerve conduction velocity (MCV) of peripheral
nerves was measured by standardized techniques using
Nicolet VikingQuest (Nicolet Biomedical Inc., Madison,
WI) at the latest follow-up. In brief, for MCV of the
median nerve, supramaximal stimuli were applied to the
elbow, and the compound muscle action potential was
recorded from surface electrodes placed over the abductor
pollicis brevis muscle. To evaluate the MCV of the sciatic
nerve, F-wave conduction velocity (FWCV) of the tibial
nerve was used, according to Kimura et al [8]. F responses
were recorded with surface electrodes over the abductor
hallucis, following supramaximal stimulation at the
ankle. A total of 16 F-waves were recorded and minimal F-
wave latency was determined.
Follow-up and statistical analysis
The time of follow-up was calculated from the date of the
operation. All survival analyses were evaluated with the
Kaplan-Meier product-limit method. The median follow-
up period was 4 years (range, 13–77 months).
Results
Oncological outcomes
There was one local failure and one distant failure during
patients' clinical courses (Table 2). Patient 2 developed a
local recurrence outside the PTV of brachytherapy 25
months postoperatively. This failure was successfully sal-
vaged with complete resection of the recurrent lesion and
50 Gy of adjuvant EBRT, but the patient experienced a
femoral shaft fracture 32 months later. Patient 6 died of
progressive pulmonary metastases but with local control
maintained. Patient 7 died of heart problems. The other
four patients survived and continued to be disease-free.
The 5-year actuarial overall survival, disease-free survival,
and local control rates were 83.3, 68.6, and 83.3%,
respectively.
Complications
Two patients had nerve-associated complications at the
time of follow-up (Table 2). Patient 1 developed an
immediate postoperative palsy of the anterior interos-
seous nerve prior to brachytherapy. Patient 5 had experi-
enced sensory loss of the tibial nerve since before
treatment, possibly caused by the lesion compressing the
tibial nerve. In both cases, these complications have been
improving. Therefore, there was no practical evidence of
HDR brachytherapy-induced neurotoxicity. Complica-
tions other than nerve-associated problems included the
above-mentioned femoral shaft fracture.
To further investigate the subclinical nerve damage by
HDR brachytherapy, MCV studies were carried out. Of five
survivors, two patients who had radiation-unrelated neu-
ropathy were excluded. The MCV value of the medianBMC Cancer 2005, 5:79 http://www.biomedcentral.com/1471-2407/5/79
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nerve and FWCV values of the tibial nerves (for MCV of
the sciatic nerves) were in the normal range [8,9], consist-
ent with our clinical findings (Table 3).
Discussion
Brachytherapy has many theoretical and practical advan-
tages, compared to EBRT. The shorter overall treatment
time offers the patient conveniences and reduces the
financial cost of treatment [10], in contrast to the standard
7–8 week course of EBRT. The rapid dose fall-off of brach-
ytherapy spares more surrounding normal tissues [5].
Several large clinical studies have demonstrated the effi-
cacy of conventional low-dose-rate (LDR) brachytherapy
as an adjuvant therapy for STS. LDR brachytherapy pro-
vided adequate local control and acceptable morbidity
compared favorably with those of EBRT [11,12]. Accord-
ing to prospective randomized trials, adjuvant brachyther-
apy improves local control after complete resection of soft
tissue sarcomas. This improvement is limited to patients
with high-grade histopathology [6,13]. Following these
reports, we have been treating only high-grade soft tissue
sarcoma with adjuvant brachytherapy after 1996. In this
study, Patient 5 with a low-grade lesion received adjuvant
brachytherapy in 1995. Regarding the direct effect of LDR
brachytherapy on peripheral nerves, it has been reported
that none of the 38 patients with STS involving the neu-
rovascular bundle developed radiation neuropathy after
receiving conservative tumor resection and cumulative
doses less than 9,000 cGy of LDR brachytherapy com-
bined with or without EBRT [14]. A histological and elec-
trophysiological study using rabbits observed that
irradiation by iridium-192 LDR brachytherapy to doses
up to 13,000 cGy on the carotid-sheath contents includ-
ing the vagus nerve was well tolerated [15].
Compared to LDR brachytherapy the use of HDR is an
attractive alternative, because this technique allows treat-
ment to be given in minutes instead of days, eliminating
the radiation hazards and prolonged hospital stays associ-
ated with LDR. HDR brachytherapy is expected to replace
traditional LDR brachytherapy, although there is limited
experience in the use of HDR, both in terms of the dura-
tion and the number of cases, compared to LDR [16,17].
Further clinical data are needed to determine the specific
role of HDR in the management of STS. There are no clin-
ical reports, which properly evaluate HDR brachytherapy-
inducing neuropathy, and no experimental studies on
nerve tolerance to HDR brachytherapy. In general, HDR
brachytherapy is believed to carry a large risk of nerve
damage. It has been proposed that a layer of gel-foam or
muscle should be interposed between the catheters and
the neurovascular bundles [18,19]. Nevertheless, the
results of our study showed that there was no practical and
electrophysiological finding of neurotoxicity of HDR
brachytherapy. Based on their clinical study [14], Zelefsky
et al. speculated that the threshold tolerance of peripheral
nerves to LDR brachytherapy might be higher than to
EBRT. Similarly, HDR brachytherapy may have a higher
threshold tolerance than EBRT, attributable to different
radioactive sources.
Despite the small number of patients, our findings suggest
that HDR brachytherapy may not adversely affect periph-
eral nerve function in the treatment of STS with neurovas-
cular involvement. Latency also needs to be considered in
evaluation of radiation neuropathy. A long-term follow-
up study of EBRT reported that the incidence of complica-
tions involving nerves increased with time after radiation
and not all of the cases were detected at 5, or even 10 years
after the treatment [20]. More clinical data with a large
number of patients treated with HDR brachytherapy and
longer follow-up periods are required to detect further
long-term morbidity.
Conclusion
In this study, there was no practical and electrophysiolog-
ical finding of neurotoxicity of HDR brachytherapy.
Despite the small number of patients, our encouraging
results are valuable for limb-preserving surgery of unman-
ageable STS involving critical neurovascular structures.
Table 3: Electrophysiological results
No. Preserved nerve Motor nerve or F-wave conduction velocity (m/s) Months after 
brachytherapy
Involved limb Uninvolved limb
2 Sciatic nerve 50.3 52.3 75
3 Median nerve 55.0 56.0 62
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